Aggregator
‘Anti-woke’ policies blamed for falling attendance at some US conferences
What happened at COP30? 4 science take-homes from the climate summit
Thirty years of Bose–Einstein condensation
World leaders must find the courage to end the fossil-fuel age
Earthquakes, hurricanes and floods: protecting the people who live in hazardous places
Author Correction: An asymmetric fission island driven by shell effects in light fragments
Polyclonal origins of human premalignant colorectal lesions
Author Correction: Spatial fibroblast niches define Crohn’s fistulae
Anti-uPAR CAR T cells reverse and prevent aging-associated defects in intestinal regeneration and fitness
Don’t scrap climate COPs, reform them
This AI combo could unlock human-level intelligence
International environmental treaties cannot be reformed through rational design
Universities must help students faced with the death of a supervisor
Chile must preserve international science in Antarctica
Lack of funding is pushing research in Romania to extinction
Love practically makes these birds go blind
Unusually obstructive plumage compromises the vision of two types of pheasants—a first in birds
Vampire bats may have contracted H5N1 bird flu in Peru, raising worries about further spread
Bats could form a bridge between marine and terrestrial mammals, scientists say
Accelerating science with AI
Science, Volume 390, Issue 6777, Page 965-965, December 2025.
The role of in silico and in vitro models in Parkinson's disease: Drug discovery and therapy applications
Parkinson's disease is a neurodegenerative condition, marked by a progressive deterioration in both motor and non-motor abilities, which can severely affect the quality of life of the elderly population. With no cure available, innovative tools in treatment development and drug discovery are necessary. For several years, traditional models have been essential; however, they face limitations in replicating the complex setting of Parkinson's disease. In this regard, in silico and in vitro models...
Single-nucleus and spatial transcriptomic profiling of human temporal cortex and white matter reveals key associations with AD pathology
Alzheimer's disease, the leading cause of dementia in the elderly, is a neurodegenerative disorder that has been studied to uncover therapeutic pathways through its molecular and cellular hallmarks. Here, we present a comprehensive investigation of cellular heterogeneity from the temporal cortex region of 40 individuals, comprising healthy donors and individuals with differing AD pathology. Using single-nucleus transcriptomic analysis of 430,271 nuclei from both gray and white matter of these...